<DOC>
	<DOC>NCT01045902</DOC>
	<brief_summary>The purpose of this trial is to determine the efficacy and safety of Moxifloxacin in comparison to Sulbactam/Ampicillin in the treatment of pulmonary abscesses and aspiration pneumonia.</brief_summary>
	<brief_title>BAY12-8039, iv/Oral Pulmonary Abscess/Aspiration Pneumonia</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Abscess</mesh_term>
	<mesh_term>Pneumonia, Aspiration</mesh_term>
	<mesh_term>Lung Abscess</mesh_term>
	<mesh_term>Sulbactam</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Ampicillin</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<criteria>Male or female patients aged 18 years or above The primary diagnosis is community or hospital acquired primary pulmonary abscess or aspiration pneumonia, requiring initial parenteral treatment Known hypersensitivity to fluoroquinolones and/or ÃŸlactams Patients with mechanical ventilation lasting more than 48 hours prior to enrollment, with poststenotic pneumonia, infarction pneumonia, pulmonary tuberculosis, lung abscess/pneumonia with concomitant endocarditis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Pulmonary Abscess</keyword>
	<keyword>Aspiration Pneumonia</keyword>
</DOC>